KKR and Envision completed the transaction after entering into a definitive agreement in June. The deal was valued at $9.9 billion including the assumption of debt. Envision’s stockholders will receive $46 per share of Envision common stock in cash.
As a result of the completion of the transaction, Envision’s stock stopped trading on the New York Stock Exchange before the stock exchange opened on Oct. 11.
More articles on healthcare industry transactions:
Louisiana hospital enters negotiations with Ochsner as LifePoint exits market
For-profit hospital operator M&A update: 17 latest deals involving CHS, Tenet, HCA and LifePoint
OhioHealth to assume management of 84-bed hospital
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
